

Susana García-Cerro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5310948/publications.pdf>

Version: 2024-02-01

16
papers

364
citations

933447

10
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

595
citing authors

#	ARTICLE	IF	CITATIONS
1	Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 613211.	3.5	12
2	Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice. <i>Journal of Nutrition</i> , 2020, 150, 2478-2489.	2.9	7
3	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. <i>Psychopharmacology</i> , 2020, 237, 2151-2159.	3.1	4
4	The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. <i>Journal of Psychiatric Research</i> , 2020, 126, 8-18.	3.1	9
5	Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice. <i>Journal of Nutrition</i> , 2020, 150, 1631-1643.	2.9	16
6	Early postnatal oleic acid administration enhances synaptic development and cognitive abilities in the Ts65Dn mouse model of Down syndrome. <i>Nutritional Neuroscience</i> , 2020, , 1-13.	3.1	3
7	Decreasing the Expression of GABAA $\hat{\pm}$ 5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome. <i>Molecular Neurobiology</i> , 2018, 55, 4745-4762.	4.0	15
8	Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene. <i>Neurobiology of Disease</i> , 2018, 110, 206-217.	4.4	14
9	Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. <i>Translational Psychiatry</i> , 2018, 8, 276.	4.8	12
10	Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice. <i>Brain, Behavior, and Immunity</i> , 2018, 73, 235-251.	4.1	21
11	Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome. <i>Behavioural Brain Research</i> , 2017, 334, 142-154.	2.2	14
12	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2017, 95, 91-101.	3.1	12
13	Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. <i>Neurobiology of Disease</i> , 2017, 106, 76-88.	4.4	72
14	Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder. <i>Journal of Neuroinflammation</i> , 2017, 14, 261.	7.2	42
15	Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome. <i>Neurochemical Research</i> , 2016, 41, 2904-2913.	3.3	30
16	Overexpression of Dyrk1A Is Implicated in Several Cognitive, Electrophysiological and Neuromorphological Alterations Found in a Mouse Model of Down Syndrome. <i>PLoS ONE</i> , 2014, 9, e106572.	2.5	81